API Biomarker Data Mirror DIAN’s, Support Progression Models
Cross-sectional biomarker data from the Colombian kindred confirm models of biomarker progression, but suggest an earlier drop in brain metabolism.
588 RESULTS
Sort By:
Cross-sectional biomarker data from the Colombian kindred confirm models of biomarker progression, but suggest an earlier drop in brain metabolism.
Measuring total prion protein in cerebrospinal fluid could help clinicians differentiate between prion disease and rapidly progressing forms of dementia.
Scientists claim that MRI detects an Aβ oligomer-specific probe delivered to the mouse brain through the nose.
Researchers at CTAD added to growing evidence that brain amyloid accumulation presages cognitive decline, although several different factors influence how fast that decline will happen in a given person.
Researchers at CTAD advanced tau research on several fronts, correlating tau PET with Braak stage and memory loss, and introducing a new tau model and therapeutic antibody.
A sense of change on all fronts pervaded the Clinical Trials on Alzheimer’s Disease conference. Scientists shared their early experiences of what works and what does not as they begin trials with newly defined cohorts, new diagnostic criteria, and new outcomes.
Using physiological measurements, researchers are tracing behavior changes in frontotemporal dementia back to crumbling neural circuitry.
By beaming red light at a blood sample and measuring the scattered photons, scientists claim to identify people with Alzheimer’s disease.
Introducing a clinical trials database for ALS that encompasses nearly 9,000 patient records, the organizers tease with the first few findings.
People who lose their sense of smell have triple the odds of dying within five years. Some speculate neurodegenerative disease is involved.
Data suggest Aβ-dependent and –independent pathways combine forces to compromise cognition in otherwise healthy people.
When strict quality control standards are followed, low Aβ in cerebrospinal fluid accurately predicts amyloid plaques in people with cognitive impairment in clinical practice.
Compounds that bind RNA temper toxicity related to ALS and FTD.
Connections across neural networks break down as cognition declines in people with different forms of AD, suggesting the wiring problems may be a hallmark of disease progression.
Researchers continue to screen blood for factors that signal neurodegenerative disease.